Indeed, further analyses have revealed that GLS2 silencing substantially reduced proliferation and clonogenic potential in two MYCN-amplified neuroblastoma cell lines, Kelly and BE-2C, and attenuated their ability to form tumors in vivo. The gene discussed is MYCN; the disease is neuroblastoma.